Sera Prognostics to Showcase Innovations at J.P. Morgan Healthcare Conference 2025

Sera Prognostics Inc., renowned as The Pregnancy Company® (NASDAQ: SERA), will take center stage at the forthcoming 43rd Annual J.P. Morgan Healthcare Conference, slated for January 13-16, 2025, in the vibrant city of San Francisco. The company's President and CEO, Zhenya Lindgardt, is scheduled to deliver a detailed presentation on January 16 at 9:45 AM PT, focusing on the latest advancements and milestones achieved by Sera.

The J.P. Morgan Healthcare Conference is recognized as one of the pivotal events in the healthcare industry, attracting leading players and innovators from around the globe. During this prestigious gathering, Sera aims to highlight its commitment to enhancing maternal and neonatal health through groundbreaking pregnancy biomarker technologies. The core mission of Sera Prognostics is to provide healthcare practitioners and expectant mothers with crucial early insights that can significantly improve health outcomes and streamline healthcare costs related to pregnancy.

About Sera Prognostics

Based in Salt Lake City, Utah, Sera Prognostics stands as a frontrunner in health diagnostics, specifically targeting the nuances of maternal and child health. The company seeks to address significant challenges associated with preterm birth, which remains a pressing issue globally. Sera's innovative approach concentrates on precision pregnancy care, ensuring that relevant information reaches healthcare providers timely and accurately.

Innovations Ready to Unfold

A key highlight of Sera's presentation will be the PreTRM® Test, which is distinguished as the only widely validated, commercially available blood biomarker test. This innovative test provides an early and precise risk assessment for spontaneous preterm birth in asymptomatic singleton pregnancies. By analyzing various proteins in the bloodstream, the PreTRM® Test empowers physicians to identify women at elevated risk of preterm birth during gestation weeks 18 to 20.

Preterm births, defined as deliveries occurring before the completion of 37 weeks of gestation, represent a leading cause of health issues and fatalities among newborns. The implications of such births are profound, with ongoing medical complications that can extend well into adulthood, including learning disabilities, chronic respiratory issues, and significant economic burdens estimated to reach around $25 billion annually in the U.S. alone.

As part of its strategic outreach, Sera will be providing a live webcast of the presentation, ensuring it is accessible to a wider audience. This allows stakeholders, investors, and healthcare professionals to engage with Sera’s vision and innovative solutions.

Continuing Commitment to Health

With the healthcare landscape continually evolving, Sera Prognostics is dedicated to being at the forefront of maternal health innovations. The insights gained from the PreTRM® Test aim to facilitate timely clinical decisions, enabling personalized care strategies that can lead to healthier pregnancy outcomes.

Through events like the J.P. Morgan Healthcare Conference, Sera Prognostics is not only promoting its technological advancements but is also fostering dialogues about essential healthcare issues, especially concerning maternal and child health. As Zhenya Lindgardt prepares to share the company’s journey and aspirations, the anticipation grows for the innovations that may reshape the future of maternity care.

In closing, Sera Prognostics continues to drive towards its goal of revolutionizing pregnancy care with a strong focus on predicting and managing risks associated with preterm births, ultimately enhancing the lives of women and their newborns across the nation and beyond.

For more details regarding the live webcast and information about Sera Prognostics, visit their official website at www.seraprognostics.com.